AURKA and renal cell carcinoma: In the case of VHL disease and RCC, it would be valuable to assess the synergistic effects of bexarotene with anti-angiogenic drugs, and with AURKA inhibitors that can rescue the ciliation defects associated with VHL deficiency (Dere et al., 2015; Hasanov et al., 2017).